S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
Log in
NASDAQ:FULC

Fulcrum Therapeutics Stock Forecast, Price & News

$12.00
-0.05 (-0.41 %)
(As of 01/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$11.28
Now: $12.00
$12.42
50-Day Range
$11.00
MA: $12.37
$13.95
52-Week Range
$7.01
Now: $12.00
$22.39
Volume137,561 shs
Average Volume200,562 shs
Market Capitalization$392.00 million
P/E RatioN/A
Dividend YieldN/A
Beta0.94
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and Ã-thalassemia. The company is also discovering drug targets for the treatments of duchenne muscular dystrophy, friedreich ataxia, myotonic dystrophy 1, and a-synucleinopathies, as well as neurological and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

MarketRank

Overall MarketRank

1.47 out of 5 stars

Medical Sector

457th out of 1,926 stocks

Pharmaceutical Preparations Industry

233rd out of 772 stocks

Analyst Opinion: 3.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FULC
CUSIPN/A
CIKN/A
Phone617-651-8851
Employees73
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.73 per share

Profitability

Net Income$-82,680,000.00

Miscellaneous

Market Cap$392.00 million
Next Earnings Date3/4/2021 (Estimated)
OptionableNot Optionable
$12.00
-0.05 (-0.41 %)
(As of 01/27/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FULC News and Ratings via Email

Sign-up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Fulcrum Therapeutics (NASDAQ:FULC) Frequently Asked Questions

How has Fulcrum Therapeutics' stock price been impacted by COVID-19?

Fulcrum Therapeutics' stock was trading at $11.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, FULC shares have increased by 8.1% and is now trading at $12.00.
View which stocks have been most impacted by COVID-19
.

Is Fulcrum Therapeutics a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulcrum Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Fulcrum Therapeutics stock.
View analyst ratings for Fulcrum Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Fulcrum Therapeutics?

Wall Street analysts have given Fulcrum Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Fulcrum Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Fulcrum Therapeutics' next earnings date?

Fulcrum Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 4th 2021.
View our earnings forecast for Fulcrum Therapeutics
.

How were Fulcrum Therapeutics' earnings last quarter?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) issued its earnings results on Tuesday, November, 10th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by $0.04. The firm had revenue of $1.85 million for the quarter, compared to the consensus estimate of $2 million.
View Fulcrum Therapeutics' earnings history
.

What price target have analysts set for FULC?

7 brokers have issued 1 year price objectives for Fulcrum Therapeutics' stock. Their forecasts range from $11.00 to $23.00. On average, they expect Fulcrum Therapeutics' stock price to reach $18.17 in the next twelve months. This suggests a possible upside of 51.4% from the stock's current price.
View analysts' price targets for Fulcrum Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Fulcrum Therapeutics' key competitors?

What other stocks do shareholders of Fulcrum Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulcrum Therapeutics investors own include VIVUS (VVUS), (PCSA), Provention Bio (PRVB), Entasis Therapeutics (ETTX), Kaleido Biosciences (KLDO), VBI Vaccines (VBIV), Xeris Pharmaceuticals (XERS), CymaBay Therapeutics (CBAY), Evelo Biosciences (EVLO) and Akero Therapeutics (AKRO).

Who are Fulcrum Therapeutics' key executives?

Fulcrum Therapeutics' management team includes the following people:
  • Dr. Robert J. Gould, CEO, Pres & Director (Age 66, Pay $778.2k)
  • Mr. Bryan E. Stuart, Chief Operating Officer (Age 45, Pay $589.84k)
  • Dr. Owen B. Wallace, Chief Scientific Officer (Age 52, Pay $507.46k)
  • Dr. Bradley E. Bernstein, Founder
  • Dr. Michael R. Green, Founder
  • Prof. Rudolf Jaenisch, Founder
  • Prof. Jeannie T. Lee M.D., Ph.D., Founder
  • Dr. Danny Reinberg, Founder
  • Mr. Peter G. Thomson, VP of Fin. & Accounting
  • Ms. Nicole T. Gallagher, Sr. Mang. of Admin. Services

When did Fulcrum Therapeutics IPO?

(FULC) raised $76 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 4,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink served as the underwriters for the IPO.

What is Fulcrum Therapeutics' stock symbol?

Fulcrum Therapeutics trades on the NASDAQ under the ticker symbol "FULC."

How do I buy shares of Fulcrum Therapeutics?

Shares of FULC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Fulcrum Therapeutics' stock price today?

One share of FULC stock can currently be purchased for approximately $12.00.

How big of a company is Fulcrum Therapeutics?

Fulcrum Therapeutics has a market capitalization of $392.00 million. The company earns $-82,680,000.00 in net income (profit) each year or ($8.13) on an earnings per share basis. Fulcrum Therapeutics employs 73 workers across the globe.

What is Fulcrum Therapeutics' official website?

The official website for Fulcrum Therapeutics is www.fulcrumtx.com.

How can I contact Fulcrum Therapeutics?

Fulcrum Therapeutics' mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-651-8851 or via email at [email protected]

This page was last updated on 1/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.